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Abstract
Background Ultrasound (US) is a real-time non-invasive technique that has been demonstrated to support an early
diagnosis and a more precise assessment of hidradenitis suppurativa (HS).
Objectives To compare the clinical and US evaluation of a series of HS patients.
Methods 434 HS patients (259 F, 175 M; mean age 33.82 13.31 years) observed across 19 Italian dermatology cen-
tres [members of the Italian Ultrasound Working Group (IUWG)] were enrolled in a retrospective study. Clinical staging
was obtained by the Hidradenitis Suppurativa Physician’s Global Assessment score (HS-PGA), while the ultrasono-
graphic staging was determined by the US HS-PGA, based on the same scores as clinical HS-PGA but performed with
the aid of US.
Results At the end of the study, the mean clinical and US HS-PGA scores were 2.70 and 2.92, respectively. Direct
comparison of clinical and ultrasonographic assessment revealed that a higher proportion of patients was classified as
having moderate and very severe disease by US. In particular, 117 patients (26.96%) had a worse classification by US
HS-PGA compared to clinical assessment.
Conclusion Our findings confirm that the use of clinical grading only to assess HS severity may underestimate the real
disease severity. US examination can be considered an essential non-invasive imaging tool available to dermatologists
for a more accurate diagnosis, staging, treatment planning and monitoring of HS and should be included in the pathway
to an optimal standard of care of HS.
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Introduction
The current classifications and staging systems of HS are based
on the clinical recognition, count and localization of the cuta-
neous lesions.1 Although additional clinical information has
been suggested,2,3 overall simple clinical evaluation may under-
estimate the real extent and severity of the disease.4,5
Ultrasound (US) is a real-time non-invasive technique that
has expanding uses in dermatology and that in the last few years
has been applied in the study of HS, being useful for a better and
clearer identification of clinical and subclinical lesions.6–13
The Italian Ultrasound Working Group (IUWG) includes a
series of dermatologists specifically trained in the use of US for
skin disorders who are in charge of enhancing and diffusing the
use of US in HS.†See Appendix for Italian Ultrasound Working Group.
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Different studies have suggested that US may help in HS man-
agement by enhancing the visualization and the extension of dif-
ferent cutaneous lesions, so to support an early diagnosis and a
more precise assessment of disease severity.8,14–16
A series of US criteria for the diagnosis of HS have been pro-
posed in 2013 by Wortsman et al.6 that include the presence of
hair follicles widening, dermal alterations, pseudocysts, fluid col-
lections and fistulae. The authors suggested that the positivity
for three or more of these findings is diagnostic for HS. They
also proposed a 3-point sonographic scoring system for HS
(SOS-HS) to define disease severity that is based on the number
and distribution of fluid collections, fistulous tracts, pseudocys-
tic nodules, widening of the hair follicles and alterations in the
dermal thickness/echogenicity.6,7 In their experience, the use of
the SOS-HS scoring system in the staging of HS patients resulted
in a management modification in 82% of cases; in particular, in
24% of cases it changed from medical to surgical.6
More recently, a consensus of international experts validated
five key lesions detectable by US: pseudocyst, fluid collection, fis-
tulous tract, connected fistulous tracts and hair tracts, and rec-
ommended the routine use of the colour Doppler function
during US examination.12 Doppler activity in the elementary
lesions indicates the presence of inflammation that may be cru-
cial in choosing the correct therapeutic approach.10,17,18
US is also useful in treatment monitoring and follow-up13,19,20
with the first sign of treatment response being represented by the
decrease of inflammatory activity at colour Doppler. Other US
signs of disease improvement include reduction/disappearance of
fluid collections and fistulous tracts, and the likely presence of
residual scarring appearing as epidermal and dermal parallel
hyperechoic areas.8,13,19 A study on 40 HS patients evaluating the
treatment response in different subtypes of fistulae, highlighted
the importance of US in therapeutic planning: dermal and der-
moepidermal fistulae showed a complete resolution after
6 months of different medical therapies in up to 95% and 65% of
cases, respectively, whereas complex and subcutaneous fistulae
showed no significant response after a medical intervention.21
In a recent study, the IUWG collected retrospective data com-
paring clinical and US evaluation of 124 HS patients (53 M, 71
F; 33.6  13.6 years).22 Clinically, disease severity was assessed
by two validated scores: the Hurley staging system, graded using
a 3-point scale (I-III), and the Hidradenitis Suppurativa Physi-
cian’s Global Assessment score (HS-PGA), based on a 6-point
scale22 (Table 1). Similarly, US evaluation was performed using
the aforementioned SOS-HS and a new proposed scoring sys-
tem, the US HS-PGA, based on the same scores as clinical HS-
PGA but performed with the aid of US. At the end of the study,
28.7% of patients were classified as more severe using SOS-HS
compared to Hurley scoring. Concordantly, US HS-PGA com-
pared to clinical HS-PGA classified 13.7% patients as being more
severe. These results confirmed US as a complementary but very
useful test to clinical assessment, particularly in severe patients,
and indicated for the first time US HS-PGA as a new staging sys-
tem that allows an easy comparison with its clinical counterpart,
the validated HS-PGA.22
Italian ultrasound working group: retrospective
study
Introduction
Based on the preliminary results of the aforementioned study by
Napolitano et al.,22 the IUWG has encouraged and supported
the use of US in HS in several Italian centres. Herein, we report
the results of the extension of the previous IUWG study. The
aim was to compare clinical HS-PGA with US HS-PGA in the
evaluation of HS patients in a large cohort of patients.
Methods
In this retrospective study, data from 434 HS patients observed
across 19 Italian dermatology centres members of the IUWG
were analysed. For this purpose, a specific digital platform was
implemented by ‘The System Academy’ agency (Florence, Italy),
whose support was restricted to data collection only. Patients
provided informed consent and, in order to ensure anonymity,
each has been assigned a code number. Data of the aforemen-
tioned IUWG study by Napolitano et al.22 are part of the present
study. Disease severity was assessed clinically by HS-PGA and
ultrasonographically by the US HS-PGA. All US operators were
dermatologists experienced with HS that followed the same
Table 1 Hidradenitis suppurativa physician global assessment (HS-PGA)
HS-PGA Definition
Clear (score = 0) No abscesses, no draining fistulae, no inflammatory nodules, no non-inflammatory nodules
Minimal (score = 1) No abscesses, no draining fistulae, no inflammatory nodules but presence of non-inflammatory nodules
Mild (score = 2) No abscesses, no draining fistulae, and 1–4 inflammatory nodules, or 1 abscess or draining fistula and no
inflammatory nodules
Moderate (score = 3) No abscesses, no draining fistulae, and ≥5 inflammatory nodules, or 1 abscess or draining fistula and ≥1
inflammatory nodules, or 2–5 abscesses or draining fistulae and <10 inflammatory nodules
Severe (score = 4) 2–5 abscesses or draining fistulae and ≥10 inflammatory nodules
Very severe (score = 5) >5 abscesses or draining fistulae
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training and used a 14–20 MHz US transducer equipped with
power and colour Doppler (MyLabTM One, Esaote, Genoa, Italy).
US examination focused on the recognition of those features
that contribute to build-up the HS-PGA grading: pseudocyst
(round or oval shaped hypoechoic or anechoic nodular dermal
and/or hypodermal structure < 1 cm), fluid collection (hypoe-
choic or anechoic fluid dermal and/or hypodermal saclike struc-
ture connected to the base of widened hair follicles), fistulous
tract (hypoechoic or anechoic dermal and/or hypodermal band-
like structure connected to the base of widened hair follicles)
and connected fistulous tracts (two or more connected fistulous
tracts in the same region) (Fig. 1). The use of power/colour
Doppler allowed the recognition of inflammatory vs non-inflam-
matory lesions (Fig. 2). The study was conducted in accordance
with the latest version of the Declaration of Helsinki
Results
Among 434 patients, the majority were female (259; 59.7%) and
the mean age was 33.82  13.31 years. Patients presented an
average of 1.6 affected regions (range: 1–6), thereof most
affected regions were armpit (226/694 = 32.56%) and groin
(223/694 = 32.13%). The most frequent comorbidities were
acne (129/353 = 36.54%) and diabetes (26/434 = 6.22%). The
mean clinical and US HS-PGA scores were 2.70 and 2.92, respec-
tively. Direct comparison of clinical and ultrasonographic assess-
ment revealed that a higher proportion of patients was classified
as having from moderate to very severe disease by US (Fig. 3).
In particular, 117 patients (26.96%) had a worse classification by
US HS-PGA compared to clinical assessment.
Discussion
Our study represents to date the largest data collection evaluat-
ing the concordance between clinical and US examination in
determining HS staging. The results confirm that the use of clin-
ical grading only to assess HS severity may underestimate the
real disease severity. In particular, US revealed more severe HS
cases than clinical examination by allowing a better categoriza-
tion of clinical manifestations (e.g. nodules vs. abscesses vs. fis-
tulae) and/or the detection of clinically undetected lesions.
Unlike the previous study by Wortsman et al.,6 which used dif-
ferent clinical and US scores (Hurley vs. SOS-HS), our study
compared two similar clinical and US scores (clinical HS-PGA
vs. US HS-PGA), thus reducing possible bias. Although several
other clinical scores are available for HS staging, such as refined
Hurley score, modified Sartorius score, international HS severity
Figure 1 Ultrasound aspect of different HS lesions: (a) pseudo-
cyst (b) fluid collection with hair tract (arrow) (c) fistulous tract (d)
connected fistulous tracts.
Figure 2 Ultrasound aspect of a fluid collection (a) and colour Doppler evaluation (b).
Figure 3 Results: clinical and US HS-PGA scores of 434 HS
patients.
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score system (IHS4), HS clinical response (HiSCR) and severity
assessment of HS (SAHS), HS-PGA represents a simple but
detailed score that stratifies patients in six groups (from clear to
very severe), allowing an easy comparison between clinical and
US data.
Our results are similar to that obtained by a recent Spanish
multicentre study comparing clinical vs. US assessment of Hur-
ley staging system in 143 HS patients.23 With the aid of US, the
staging changed to a more severe stage in 44.7% of patients who
were diagnosed as having Hurley stage I through clinical exami-
nation. In particular, on clinical examinations 26.6% of patients
had Hurley stage I, 49% stage II and 24.5% stage III; conversely,
US examination classified 14.7% of patients as Hurley stage I,
55.9% as stage II and 29.4% as stage III.
Conclusions
US examination can be considered an essential non-invasive
imaging tool available to dermatologists for more accurate diag-
nosis, staging, treatment planning and monitoring of HS (Figs 4
and 5) and should be included in the pathway to an optimal stan-
dard of care of HS. From our study, it emerges how essential it is
to combine routine clinical assessment with US evaluation, partic-
ularly in patients with more severe disease that often harbour
underlying lesions that may go undetected by simple palpation.
The correct use of US in HS requires specific training, but the
recognition of the key lesions (pseudocyst, fluid collection, fistu-
lous tract, connected fistulous tracts and hair tracts) is quite sim-
ple, as is the use of power or colour Doppler for the evaluation
of inflammatory lesions. Undoubtedly, the use of US in HS
requires a longer time than simple clinical examination, but it
has the advantage of provinding the physician with a more
accurate and complete evaluation. The recent introduction of
standardized US nomenclature and reporting in HS12 could sup-
port US integration in clinical practice.
We finally suggest to consider the use of the novel scoring sys-
tem US HS-PGA, in order to objectively compare, reproduce
and analyse data between different study centres.
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Appendix
Italian Ultrasound Working Group: Giuseppe Argenziano (Der-
matology Unit, University of Campania, Naples, Italy); Emilio
Berti (Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospe-
dale Maggiore Policlinico, Milan, Italy); Luca Bianchi (Depart-
ment of Dermatology, University of Rome Tor Vergata, Rome,
Italy); Piergiacomo Calzavara Pinton (Department of Dermatol-
ogy, University of Brescia, Italy); Serafinella Patrizia Cannavo`
(Section of Dermatology, University of Messina, Italy); Antonio
Costanzo (Dermatology Unit, Humanitas University and Huma-
nitas Clinical and Research Center, Rozzano, Italy); Massimo
Donini (Department of Dermatology, SS Giovanni e Paolo Civil
Hospital, Venice, Italy); Gabriella Fabbrocini (Section of Derma-
tology, Department of Clinical Medicine and Surgery, University
of Naples Federico II, Naples, Italy); Maria Teresa Fierro
(Department of Medical Sciences, University Clinic of Derma-
tology, Turin, Italy); Giuseppe Micali (Dermatology Clinic, Uni-
versity of Catania, Italy); Annamaria Offidani (Dermatology
Unit, Polytechnic Marche University, Ancona, Italy); Aurora
Parodi (Di.S.Sal. Section of Dermatology, University of Genoa,
Italy); Annalisa Patrizi (Division of Dermatology, University of
Bologna, Italy); Giovanni Pellacani (Dermatology Unit, Univer-
sity of Modena and Reggio Emilia, Modena, Italy); Ketty Peris
(Institute of Dermatology, Catholic University, Fondazione Poli-
clinico Universitario A. Gemelli IRCCS, Rome, Italy); Nicola
Pimpinelli (Division of Dermatology, University of Florence,
Italy); Concetta Potenza (Dermatology Unit ‘Daniele Innocenzi’,
Sapienza University of Rome, Polo Pontino, Terracina, Italy);
Marco Romanelli (Department of Dermatology, University of
Pisa, Italy); Franco Rongioletti (Dermatology Clinic, University
of Cagliari, Italy); Francesco Solivetti (Radiodiagnostic Service,
Dermatologic Institute San Gallicano, Rome, Italy).
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